NovoCure Limited announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was USD 133.517 million compared to USD 115.925 million a year ago. Operating loss was USD 12.295 million compared to operating Income of USD 6.668 million a year ago. Net loss was USD 14.641 million compared to net income of USD 1.655 million a year ago. Basic loss per share from continuing operations was USD 0.14 compared to basic earnings per share from continuing operations of USD 0.02 a year ago. For the half year, sales was USD 268.212 million compared to USD 217.753 million a year ago. Operating loss was USD 12.383 million compared to operating Income of USD 3.287 million a year ago. Net loss was USD 18.769 million compared to net income of USD 5.607 million a year ago. Basic loss per share from continuing operations was USD 0.18 compared to basic earnings per share from continuing operations of USD 0.06 a year ago. Diluted loss per share from continuing operations was USD 0.18 compared to diluted earnings per share from continuing operations of USD 0.05 a year ago.